Suven Life secures 2 product patents in Canada, 1 in China
16 Sep 2015
Suven Life Sciences Ltd (Suven) has received two product patents from Canada and one from China for the new chemical entities (NCEs) developed for the treatment of disorders associated with Neurodegenerative diseases.
The patents – No 2773409,2785957 granted by Canada and No CN102741239 (China) - correspond to the new chemical entities (NCEs) developed by the company for the treatment of disorders associated with neurodegenerative diseases.
These patents are valid through 2029 and 2030.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD), the company said in a release.
With these new patents, Suven calims to have a total of 20 granted patents from Canada and 18 granted patents from China.
''These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,'' the company said.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder (MDD) with high unmet medical need with huge market potential globally'' says Venkat Jasti, CEO of Suven.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.
Suven has 3 clinical stage compounds, a Phase 2 initiated candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 initiated candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia.
In addition, the company has 10 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.
